UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the Financial Period Ended 30 Jun 2025
Commission
File Number: 001-41677
CytoMed
Therapeutics Limited
(Exact
name of registrant as specified in its charter)
1
Commonwealth Lane
#08-22
Singapore
149544
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Yes ☒ No ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes ☐ No ☒
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes ☐ No ☒
INFORMATION
CONTAINED IN THIS FORM 6-K REPORT
CytoMed
Therapeutics Limited (the “Company”) is hereby furnishing this report on Form 6-K (the “Report”) to provide the
Unaudited Interim Condensed Consolidated Financial Statements of the Company for the six months ended June 30, 2025, included as Exhibit
99.1 of this Report, and the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the
six months ended June 30, 2025, included as Exhibit 99.2 of this Report.
Conference
Call Information
A
conference call to discuss the Company’s financial results via Zoom is scheduled for October 2, 2025 at 10 a.m. ET. The investment
community may participate in the conference call by tuning into the following Zoom:
https://us06web.zoom.us/j/86967286296?pwd=Xls7XQsRWteN6eXpgRrkqajaL35aHX.1
Exhibits
| Exhibit
No. |
|
Description |
| |
|
|
| 99.1 |
|
Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2025 |
| |
|
|
| 99.2
|
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2025 |
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
| |
CytoMed
Therapeutics Limited |
| |
|
|
| |
By: |
/s/
CHOO Chee Kong |
| |
Name: |
CHOO
Chee Kong |
| Date:
September 30, 2025 |
Title: |
Director
and Chairman |
